MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer
  • 4 月 5, 2022
    AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
  • 4 月 5, 2022
    Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
  • 4 月 5, 2022
    对晚期实体瘤患者进行的 GSK4381562 首次人体研究
  • 4 月 5, 2022
    Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
  • 4 月 5, 2022
    Repotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
  • 4 月 5, 2022
    最初无法切除肝转移灶的 RAS/BRAF 野生型结直肠癌患者的转换疗法